William J. Chase's most recent trade in Intellia Therapeutics Inc was a trade of 100,000 Common Stock done at an average price of $10.0 . Disclosure was reported to the exchange on Aug. 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | William J. Chase | Director | Purchase of securities on an exchange or from another person at price $ 10.03 per share. | 20 Aug 2025 | 100,000 | 134,693 (0%) | 0% | 10.0 | 1,003,000 | Common Stock |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 38.53 per share. | 15 Jul 2025 | 533 | 36,315 | - | 38.5 | 20,536 | Common Stock |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,450 | 11,450 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 8,000 | 34,693 (0%) | 0% | 0 | Common Stock | |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 41.10 per share. | 29 May 2025 | 6,082 | 35,782 | - | 41.1 | 249,970 | Common Stock |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 25.94 per share. | 15 Apr 2025 | 784 | 29,700 | - | 25.9 | 20,337 | Common Stock |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 17.58 per share. | 15 Jan 2025 | 1,182 | 28,916 | - | 17.6 | 20,780 | Common Stock |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 13.62 per share. | 30 Oct 2024 | 210 | 27,734 | - | 13.6 | 2,860 | Common Stock |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 14.01 per share. | 15 Oct 2024 | 1,054 | 27,524 | - | 14.0 | 14,767 | Common Stock |
| GRAIL Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 26,470 | 26,470 | - | 0 | Common Stock | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 11,515 | 11,515 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 7,737 | 26,693 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,447 | 2,447 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 1,673 | 18,956 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 14,931 | 14,931 | - | - | Stock Option (Right to Buy) | |
| Intellia Therapeutics Inc | William J. Chase | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 10,483 | 17,283 (0%) | 0% | 0 | Common Stock |